Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

August 31, 2026

Conditions
Opioid WithdrawalOpioid Use Disorder (OUD)
Interventions
DEVICE

Sparrow Link (Active tAN)

Participants will receive the Sparrow Link device with active transcutaneous auricular neurostimulation (tAN) in addition to standard hospital-based opioid withdrawal management. Standard care may include pharmacologic treatments such as methadone, buprenorphine, full agonist opioids (e.g., oxycodone), and non-opioid medications, as clinically indicated.

DEVICE

Sparrow Link (Sham tAN)

Participants will receive the Sparrow Link device with sham (non-active) stimulation in addition to standard hospital-based opioid withdrawal management. Standard care may include pharmacologic treatments such as methadone, buprenorphine, full agonist opioids (e.g., oxycodone), and non-opioid medications, as clinically indicated.

Trial Locations (1)

15213

UPMC Presbyterian, Pittsburgh

All Listed Sponsors
collaborator

UPMC Ladies Hospital Aid Society

UNKNOWN

lead

Payel Roy

OTHER

NCT07079826 - Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder | Biotech Hunter | Biotech Hunter